Robert W. Baird started coverage on shares of Cambrex (NYSE:CBM) in a report issued on Thursday, The Fly reports. The brokerage set an “outperform” rating on the biotechnology company’s stock.

CBM has been the topic of a number of other research reports. First Analysis raised shares of Cambrex from an “outperform” rating to a “strong-buy” rating and cut their target price for the company from $73.00 to $63.00 in a research report on Friday, November 9th. Zacks Investment Research raised shares of Cambrex from a “hold” rating to a “strong-buy” rating and set a $73.00 target price on the stock in a research report on Wednesday, August 8th. Finally, Jefferies Financial Group assumed coverage on shares of Cambrex in a research report on Tuesday, September 25th. They set a “buy” rating and a $75.50 target price on the stock. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $70.50.

NYSE CBM traded down $0.37 during trading on Thursday, reaching $47.43. 479,596 shares of the company’s stock traded hands, compared to its average volume of 359,714. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.41 and a current ratio of 4.54. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of 14.96, a price-to-earnings-growth ratio of 1.73 and a beta of 2.42. Cambrex has a 12-month low of $44.92 and a 12-month high of $69.43.

Cambrex (NYSE:CBM) last posted its earnings results on Thursday, November 8th. The biotechnology company reported $0.49 EPS for the quarter, missing analysts’ consensus estimates of $0.59 by ($0.10). The business had revenue of $104.62 million for the quarter, compared to analysts’ expectations of $122.04 million. Cambrex had a net margin of 22.67% and a return on equity of 22.20%. The company’s revenue for the quarter was down 7.1% on a year-over-year basis. During the same period last year, the business posted $0.55 EPS. Equities analysts expect that Cambrex will post 2.82 earnings per share for the current fiscal year.

In other news, CEO Steven M. Klosk sold 55,000 shares of Cambrex stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $66.30, for a total value of $3,646,500.00. Following the transaction, the chief executive officer now owns 138,328 shares of the company’s stock, valued at approximately $9,171,146.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Tom George Vadaketh sold 9,510 shares of Cambrex stock in a transaction that occurred on Monday, August 20th. The stock was sold at an average price of $63.42, for a total transaction of $603,124.20. Following the completion of the transaction, the chief financial officer now directly owns 9,510 shares in the company, valued at approximately $603,124.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 84,510 shares of company stock worth $5,344,824. Insiders own 2.42% of the company’s stock.

Institutional investors have recently modified their holdings of the company. BlueMountain Capital Management LLC purchased a new position in shares of Cambrex in the 3rd quarter worth approximately $144,000. Itau Unibanco Holding S.A. purchased a new position in shares of Cambrex in the 2nd quarter worth approximately $178,000. Telemus Capital LLC purchased a new position in shares of Cambrex in the 3rd quarter worth approximately $243,000. Pitcairn Co. purchased a new position in shares of Cambrex in the 3rd quarter worth approximately $253,000. Finally, Zebra Capital Management LLC purchased a new position in shares of Cambrex in the 2nd quarter worth approximately $200,000.

About Cambrex

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.

Further Reading: What are the reasons investors use put options?

The Fly

Analyst Recommendations for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.